Cargando…

Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity

BACKGROUND: Non-invasive scores, such as the non-alcoholic fatty liver disease (NAFLD) Fibrosis Score (NFS), are increasingly used for liver fibrosis assessment in patients with NAFLD. The aim of this study was to assess the applicability and reliability of non-invasive fibrosis scores in NAFLD pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drolz, Andreas, Wolter, Stefan, Wehmeyer, Malte H., Piecha, Felix, Horvatits, Thomas, Schulze zur Wiesch, Julian, Lohse, Ansgar W., Mann, Oliver, Kluwe, Johannes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455320/ https://www.ncbi.nlm.nih.gov/pubmed/34168277 http://dx.doi.org/10.1038/s41366-021-00881-8

Ejemplares similares

Nonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary pattern
por: Wehmeyer, Malte H., et al.
Publicado: (2016)

Treatment and re-treatment results of HCV patients in the DAA era
por: Piecha, Felix, et al.
Publicado: (2020)

Transjugular Intrahepatic Portosystemic Shunt: A Possible Risk Factor for Direct‐Acting Antiviral Treatment Failure in Patients With Hepatitis C?
por: Piecha, Felix, et al.
Publicado: (2019)

The Clinical Perspective on Hepatitis E
por: Horvatits, Thomas, et al.
Publicado: (2019)

Characterization of the immune cell landscape of patients with NAFLD
por: Diedrich, Tom, et al.
Publicado: (2020)

Frequent detection of functional hyposplenism via assessment of pitted erythrocytes in patients with advanced liver cirrhosis
por: Wehmeyer, Malte H., et al.
Publicado: (2022)

Ascites control by TIPS is more successful in patients with a lower paracentesis frequency and is associated with improved survival
por: Piecha, Felix, et al.
Publicado: (2019)

Stop of proton-pump inhibitor treatment in patients with liver cirrhosis (STOPPIT): study protocol for a prospective, multicentre, controlled, randomized, double-blind trial
por: Wehmeyer, Malte H., et al.
Publicado: (2022)

Therapeutic Targeting of Myeloperoxidase Attenuates NASH in Mice
por: Koop, Anja Christina, et al.
Publicado: (2020)

Non-organ-specific autoantibodies with unspecific patterns are a frequent para-infectious feature of chronic hepatitis D
por: Hermanussen, Lennart, et al.
Publicado: (2023)

Lower Levels of Transaminases but Higher Levels of Serum Creatinine in Patients with Acute Hepatitis E in Comparison to Patients with Hepatitis A
por: Brehm, Thomas Theo, et al.
Publicado: (2021)

Low incidence of COVID-19 in a prospective cohort of patients with liver cirrhosis and hepatocellular carcinoma treated at a tertiary medical center during the 2020 pandemic
por: Fründt, Thorben, et al.
Publicado: (2021)

Significance of Anti-Nuclear Antibodies and Cryoglobulins in Patients with Acute and Chronic HEV Infection
por: Horvatits, Thomas, et al.
Publicado: (2020)

Predictors for advanced fibrosis in morbidly obese non-alcoholic fatty liver patients
por: Zelber-Sagi, Shira, et al.
Publicado: (2017)

Safety and efficacy of protease inhibitor based combination therapy in a single-center “real-life” cohort of 110 patients with chronic hepatitis C genotype 1 infection
por: Wehmeyer, Malte H, et al.
Publicado: (2014)

High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection: longitudinal analysis of a German cohort
por: Bockmann, Jan-Hendrik, et al.
Publicado: (2020)

TREM2 Regulates the Removal of Apoptotic Cells and Inflammatory Processes during the Progression of NAFLD
por: Liebold, Imke, et al.
Publicado: (2023)

Clinical impact and outcome of clostridium non-difficile infection in critically ill patients
por: Rutter, K, et al.
Publicado: (2015)

Risk factors for worsening of somatic symptom burden in a prospective cohort during the COVID-19 pandemic
por: Engelmann, Petra, et al.
Publicado: (2022)

SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients
por: Ruether, Darius F., et al.
Publicado: (2022)

Increased Expression of Complement Regulators CD55 and CD59 on Peripheral Blood Cells in Patients with EAHEC O104:H4 Infection
por: Dammermann, Werner, et al.
Publicado: (2013)

Hepcidin in morbidly obese women with non-alcoholic fatty liver disease
por: Auguet, Teresa, et al.
Publicado: (2017)

Non-invasive fibrosis assessment in non-alcoholic fatty liver disease
por: Rios, Rafael S., et al.
Publicado: (2020)

Machine learning to predict progression of non‐alcoholic fatty liver to non‐alcoholic steatohepatitis or fibrosis
por: Ghandian, Sina, et al.
Publicado: (2022)

High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities
por: Bockmann, Jan-Hendrik, et al.
Publicado: (2021)

Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease
por: Basheer, Maamon, et al.
Publicado: (2023)

Metabolism of cyclic GMP in non-alcoholic fatty liver disease in morbid obesity
por: Urios, Amparo, et al.
Publicado: (2011)

Thyroid Function and the Risk of Non-Alcoholic Fatty Liver Disease in Morbid Obesity
por: Borges-Canha, Marta, et al.
Publicado: (2020)

Erratum zu: Milde COVID-19-Verläufe bei Mitarbeitenden einer Universitätsklinik: Die „erste Welle“ am Universitätsklinikum Hamburg-Eppendorf
por: von Felden, Johann, et al.
Publicado: (2021)

Milde COVID-19-Verläufe bei Mitarbeitenden einer Universitätsklinik: Die „erste Welle“ am Universitätsklinikum Hamburg-Eppendorf
por: von Felden, Johann, et al.
Publicado: (2021)

Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
por: Ramai, Daryl, et al.
Publicado: (2021)

Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease
por: Daher, Saleh, et al.
Publicado: (2018)

Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease
por: Zeybel, Müjdat, et al.
Publicado: (2015)

Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic
por: Brehm, Thomas Theo, et al.
Publicado: (2021)

Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease
por: Cheah, Mark CC, et al.
Publicado: (2017)

Risk Predictors of Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease
por: Olteanu, Vasile-Andrei, et al.
Publicado: (2022)

Non-alcoholic Fatty Liver Disease and Liver Fibrosis during Aging
por: Li, Yuan, et al.
Publicado: (2022)

Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease
por: Hardy, Timothy, et al.
Publicado: (2017)

Disseminated intravascular coagulation score predicts mortality in critically ill patients with liver cirrhosis
por: Drolz, A, et al.
Publicado: (2015)

Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease
por: Tapper, Elliot B., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_h0ire3mviejb2v85bbaqiqsqvk